Tempest Therapeutics (NASDAQ:TPST) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Tempest Therapeutics (NASDAQ:TPST) from a hold rating to a sell rating in a report published on Saturday.

Separately, Zacks Research raised shares of Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Tempest Therapeutics Stock Performance

NASDAQ TPST opened at $1.83 on Friday. Tempest Therapeutics has a twelve month low of $1.50 and a twelve month high of $12.23. The stock has a market capitalization of $26.24 million, a PE ratio of -0.30 and a beta of -1.75. The stock has a 50-day simple moving average of $1.94 and a 200 day simple moving average of $3.35.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings data on Friday, May 15th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($2.25). As a group, equities research analysts forecast that Tempest Therapeutics will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Matthew Angel acquired 231,482 shares of the firm’s stock in a transaction on Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.28% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP bought a new position in Tempest Therapeutics in the 4th quarter valued at $33,000. Vanguard Group Inc. boosted its position in Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after buying an additional 27,952 shares during the last quarter. Finally, Sabby Management LLC bought a new position in Tempest Therapeutics in the 4th quarter valued at $513,000. 22.52% of the stock is currently owned by institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.